Potential of acellular biological scaffold coated with chemokines and cytokines as tissue engineered small artery grafts

涂有趋化因子和细胞因子的无细胞生物支架作为组织工程小动脉移植物的潜力

• 批准号: MR/T018208/1
• 负责人: Sarah George
• 金额: $ 44.98万
• 依托单位: University of Bristol
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FT018208%2F1
• 关键词: Potential; acellular; biological; scaffold; coated

Millions of coronary or peripheral artery bypass grafts are performed yearly worldwide by cardiac and vascular surgeons using patient's own veins from the leg (SVG) or synthetic grafts. However, >50% of these grafts get blocked after 5-10 years, with common infections at the harvesting sites and frequent hospital re-admissions. Patient's own arteries are used only in 1:5 cases due to shortage of available artery, despite >95% of these do not get blocked after 15 years. Using arterial grafts made in the lab provides hope for future patients. Our previous research suggests that implanting biological tubes made from pig or cow material into a pig graft experimental model leads to encouraging but sub-optimal results. This is an exciting development, but we need to improve the lining of the graft to reduce the occurrence of blockages. Our goal is to improve the grafts by coating the biological scaffolds with proteins able to attract cells and create a suitable lining which stops blockage by blood clots and cell growth. Our plan will allow us to achieve grafts more similar to real arteries which avoid the use of the patients own leg vein and induce the patients blood cells to create an optimal graft. This would pave the road to bringing this new technology to the bedside in 5-10 years, while saving large amount of resources to the health services and greatly improving patient's well-being and outcome.

每年，全世界心脏和血管外科医生使用患者腿部静脉 (SVG) 或合成移植物进行数百万例冠状动脉或外周动脉旁路移植术。然而，超过 50% 的移植物在 5-10 年后被阻塞，采集部位常见感染，并且经常再次入院。由于可用动脉短缺，患者自己的动脉仅在 1:5 的情况下使用，尽管其中 95% 以上的动脉在 15 年后不会被阻塞。使用实验室制造的动脉移植物为未来的患者带来了希望。我们之前的研究表明，将由猪或牛材料制成的生物管植入猪移植实验模型会产生令人鼓舞但次优的结果。这是一个令人兴奋的发展，但我们需要改进移植物的内衬，以减少堵塞的发生。我们的目标是通过在生物支架上涂上能够吸引细胞的蛋白质来改善移植物，并形成合适的内衬，阻止血凝块和细胞生长的堵塞。我们的计划将使我们能够实现更类似于真实动脉的移植物，从而避免使用患者自己的腿部静脉并诱导患者的血细胞产生最佳的移植物。这将为在 5-10 年内将这项新技术推向临床铺平道路，同时为卫生服务节省大量资源，并大大改善患者的福祉和治疗结果。

项目成果

Effective decellularisation of human saphenous veins for biocompatible arterial tissue engineering applications: Bench optimisation and feasibility in vivo testing.

• DOI: 10.1177/2041731420987529
• 发表时间: 2021-01
• 期刊: Journal of tissue engineering
• 影响因子: 8.2
• 作者: Sulaiman NS;Bond AR;Bruno VD;Joseph J;Johnson JL;Suleiman MS;George SJ;Ascione R
• 通讯作者: Ascione R

A novel small diameter nanotextile arterial graft is associated with surgical feasibility and safety and increased transmural endothelial ingrowth in pig.

• DOI: 10.1186/s12951-022-01268-1
• 发表时间: 2022-02-08
• 期刊: Journal of nanobiotechnology
• 影响因子: 10.2
• 作者: Joseph J;Domenico Bruno V;Sulaiman N;Ward A;Johnson TW;Baby HM;Kerala Varma P;Jose R;Nair SV;Menon D;George SJ;Ascione R
• 通讯作者: Ascione R

Porcine Blood Outgrowth Cells (BOCs) for Tissue Engineering of Decellularised Human Saphenous Vein Grafts

用于脱细胞人隐静脉移植组织工程的猪血生长细胞 (BOC)

• 发表时间: 2019
• 期刊: CARDIOVASCULAR DRUGS AND THERAPY
• 影响因子: 3.4
• 作者: Bond AR

Next-Generation and Single-Cell Sequencing Approaches to Study Atherosclerosis and Vascular Inflammation Pathophysiology: A Systematic Review.

• DOI: 10.3389/fcvm.2022.849675
• 发表时间: 2022
• 期刊: Frontiers in cardiovascular medicine
• 影响因子: 3.6
• 作者: McQueen LW;Ladak SS;Abbasciano R;George SJ;Suleiman MS;Angelini GD;Murphy GJ;Zakkar M
• 通讯作者: Zakkar M

BS26 Generation of a tissue engineered conduit from human saphenous vein and porcine blood outgrowth endothelial cells

BS26 从人隐静脉和猪血液生长内皮细胞生成组织工程导管

• DOI: 10.1136/heartjnl-2019-bcs.189
• 发表时间: 2019
• 作者: Bond A